Ignite Creation Date:
2025-12-24 @ 7:22 PM
Ignite Modification Date:
2025-12-29 @ 11:46 PM
Study NCT ID:
NCT01222403
Status:
COMPLETED
Last Update Posted:
2019-06-12
First Post:
2010-10-12
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Post-marketing Study to Monitor the Safety of a MF59-adjuvanted Influenza Vaccine Administered in Korean Subjects Aged 65 Years or Older
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D007251', 'term': 'Influenza, Human'}], 'ancestors': [{'id': 'D012141', 'term': 'Respiratory Tract Infections'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D009976', 'term': 'Orthomyxoviridae Infections'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'RegistryContactVaccinesUS@novartis.com', 'title': 'Posting Director', 'organization': 'Novartis Vaccines and Diagnostics'}, 'certainAgreement': {'restrictionType': 'GT60', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'Throughout the study (Day 1 through Day 28).', 'description': 'All solicited AEs and unsolicited AEs were collected from Day 1 to Day 4; all unsolicited SAEs, medically attended AEs, AEs leading to withdrawal from the study were collected from Day 1 to Day 28.', 'eventGroups': [{'id': 'EG000', 'title': 'Fluad_aTIV', 'description': 'Subjects aged \\>65 years received one dose of Fluad\\_aTIV: investigational MF59-adjuvanted trivalent influenza vaccine.', 'otherNumAtRisk': 386, 'otherNumAffected': 163, 'seriousNumAtRisk': 386, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Vantaflu_aTIV', 'description': 'Subjects aged \\>65 years received one dose of Vantaflu\\_aTIV: investigational MF59-adjuvanted trivalent influenza vaccine.', 'otherNumAtRisk': 379, 'otherNumAffected': 155, 'seriousNumAtRisk': 379, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Injection site pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 386, 'numAffected': 131}, {'groupId': 'EG001', 'numAtRisk': 379, 'numAffected': 121}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 386, 'numAffected': 29}, {'groupId': 'EG001', 'numAtRisk': 379, 'numAffected': 31}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Injection site swelling', 'stats': [{'groupId': 'EG000', 'numAtRisk': 386, 'numAffected': 17}, {'groupId': 'EG001', 'numAtRisk': 379, 'numAffected': 25}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Injection site erythema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 386, 'numAffected': 14}, {'groupId': 'EG001', 'numAtRisk': 379, 'numAffected': 21}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Chills', 'stats': [{'groupId': 'EG000', 'numAtRisk': 386, 'numAffected': 17}, {'groupId': 'EG001', 'numAtRisk': 379, 'numAffected': 20}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Myalgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 386, 'numAffected': 44}, {'groupId': 'EG001', 'numAtRisk': 379, 'numAffected': 43}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Arthralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 386, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 379, 'numAffected': 27}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 386, 'numAffected': 24}, {'groupId': 'EG001', 'numAtRisk': 379, 'numAffected': 22}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Number of Subjects Reporting Solicited Adverse Events (AEs) After Vaccination.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '386', 'groupId': 'OG000'}, {'value': '379', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Fluad_aTIV', 'description': 'Subjects aged \\>65 years received one dose of Fluad\\_aTIV: investigational MF59-adjuvanted trivalent influenza vaccine.'}, {'id': 'OG001', 'title': 'Vantaflu_aTIV', 'description': 'Subjects aged \\>65 years received one dose of Vantaflu\\_aTIV: investigational MF59-adjuvanted trivalent influenza vaccine.'}], 'classes': [{'title': 'Any Local', 'categories': [{'measurements': [{'value': '134', 'groupId': 'OG000'}, {'value': '122', 'groupId': 'OG001'}]}]}, {'title': 'Any Systemic', 'categories': [{'measurements': [{'value': '74', 'groupId': 'OG000'}, {'value': '72', 'groupId': 'OG001'}]}]}, {'title': 'Erythema (Type I)', 'categories': [{'measurements': [{'value': '14', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}]}]}, {'title': 'Erythema (Type II)', 'categories': [{'measurements': [{'value': '9', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}]}]}, {'title': 'Induration (Type I)', 'categories': [{'measurements': [{'value': '8', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}]}]}, {'title': 'Induration (Type II)', 'categories': [{'measurements': [{'value': '5', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Swelling (Type I)', 'categories': [{'measurements': [{'value': '17', 'groupId': 'OG000'}, {'value': '25', 'groupId': 'OG001'}]}]}, {'title': 'Swelling (Type II)', 'categories': [{'measurements': [{'value': '5', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}]}]}, {'title': 'Pain at injection site', 'categories': [{'measurements': [{'value': '119', 'groupId': 'OG000'}, {'value': '111', 'groupId': 'OG001'}]}]}, {'title': 'Tenderness at injection site', 'categories': [{'measurements': [{'value': '107', 'groupId': 'OG000'}, {'value': '98', 'groupId': 'OG001'}]}]}, {'title': 'Chills', 'categories': [{'measurements': [{'value': '17', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}]}]}, {'title': 'Myalgia', 'categories': [{'measurements': [{'value': '44', 'groupId': 'OG000'}, {'value': '43', 'groupId': 'OG001'}]}]}, {'title': 'Arthralgia', 'categories': [{'measurements': [{'value': '6', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}]}]}, {'title': 'Headache', 'categories': [{'measurements': [{'value': '24', 'groupId': 'OG000'}, {'value': '22', 'groupId': 'OG001'}]}]}, {'title': 'Sweating', 'categories': [{'measurements': [{'value': '8', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}]}]}, {'title': 'Fatigue', 'categories': [{'measurements': [{'value': '29', 'groupId': 'OG000'}, {'value': '31', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Day 1 through Day 4 after vaccination', 'description': 'The number of subjects reporting any solicited local and systemic AEs, following vaccination with Fluad\\_aTIV and Vantaflu\\_aTIV.', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Analysis was done on safety population ie. all subjects in the exposed set who provided postvaccination safety data.'}, {'type': 'PRIMARY', 'title': 'Number of Subjects Reporting Unsolicited AEs After Vaccination.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '386', 'groupId': 'OG000'}, {'value': '379', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Fluad_aTIV', 'description': 'Subjects aged \\>65 years received one dose of Fluad\\_aTIV: investigational MF59-adjuvanted trivalent influenza vaccine.'}, {'id': 'OG001', 'title': 'Vantaflu_aTIV', 'description': 'Subjects aged \\>65 years received one dose of Vantaflu\\_aTIV: investigational MF59-adjuvanted trivalent influenza vaccine.'}], 'classes': [{'title': 'Any AEs', 'categories': [{'measurements': [{'value': '15', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}]}, {'title': 'Possibly/probably related AEs', 'categories': [{'measurements': [{'value': '3', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Day 1 through Day 28 post vaccination', 'description': 'The number of subjects reporting any unsolicited AEs following vaccination with Fluad\\_aTIV and Vantaflu\\_aTIV.', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Analysis was done on safety population.'}, {'type': 'PRIMARY', 'title': 'Number of Subjects Reporting Unsolicited Serious Adverse Events (SAEs) After Vaccination.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '386', 'groupId': 'OG000'}, {'value': '379', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Fluad_aTIV', 'description': 'Subjects aged \\>65 years received one dose of Fluad\\_aTIV: investigational MF59-adjuvanted trivalent influenza vaccine.'}, {'id': 'OG001', 'title': 'Vantaflu_aTIV', 'description': 'Subjects aged \\>65 years received one dose of Vantaflu\\_aTIV: investigational MF59-adjuvanted trivalent influenza vaccine.'}], 'classes': [{'title': 'SAEs', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'At least possibly related SAEs', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'AEs leading to hospitalization', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'AEs leading to interruption or delay', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'AEs resulting in premature withdrawal', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Deaths', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Day 1 through Day 28 post vaccination', 'description': 'The number of subjects reporting any unsolicited AEs, SAEs, AEs leading to withdrawal (WD), AEs of special interest (AESI) following vaccination with Fluad\\_aTIV and Vantaflu\\_aTIV.', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Analysis was done on safety population.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Fluad_aTIV', 'description': 'Subjects aged \\>65 years received one dose of Fluad\\_aTIV: investigational MF59-adjuvanted trivalent influenza vaccine.'}, {'id': 'FG001', 'title': 'Vantaflu_aTIV', 'description': 'Subjects aged \\>65 years received one dose of Vantaflu\\_aTIV: investigational MF59-adjuvanted trivalent influenza vaccine.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '386'}, {'groupId': 'FG001', 'numSubjects': '381'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '386'}, {'groupId': 'FG001', 'numSubjects': '379'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '2'}]}], 'dropWithdraws': [{'type': 'Inappropriate enrollment', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '2'}]}]}], 'recruitmentDetails': 'Subjects were recruited from 24 study sites in Korea.', 'preAssignmentDetails': 'All subjects were included in the trial.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '386', 'groupId': 'BG000'}, {'value': '379', 'groupId': 'BG001'}, {'value': '765', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Fluad_aTIV', 'description': 'Subjects aged \\>65 years received one dose of Fluad\\_aTIV: investigational MF59-adjuvanted trivalent influenza vaccine.'}, {'id': 'BG001', 'title': 'Vantaflu_aTIV', 'description': 'Subjects aged \\>65 years received one dose of Vantaflu\\_aTIV: investigational MF59-adjuvanted trivalent influenza vaccine.'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '73.6', 'spread': '6.0', 'groupId': 'BG000'}, {'value': '73.2', 'spread': '6.5', 'groupId': 'BG001'}, {'value': '73.4', 'spread': '6.3', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '231', 'groupId': 'BG000'}, {'value': '225', 'groupId': 'BG001'}, {'value': '456', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '155', 'groupId': 'BG000'}, {'value': '154', 'groupId': 'BG001'}, {'value': '309', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'PREVENTION', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 767}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2010-10'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2019-05', 'completionDateStruct': {'date': '2014-10', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2019-05-31', 'studyFirstSubmitDate': '2010-10-12', 'resultsFirstSubmitDate': '2015-09-09', 'studyFirstSubmitQcDate': '2010-10-14', 'lastUpdatePostDateStruct': {'date': '2019-06-12', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2015-09-09', 'studyFirstPostDateStruct': {'date': '2010-10-18', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2015-10-12', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2014-10', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of Subjects Reporting Solicited Adverse Events (AEs) After Vaccination.', 'timeFrame': 'Day 1 through Day 4 after vaccination', 'description': 'The number of subjects reporting any solicited local and systemic AEs, following vaccination with Fluad\\_aTIV and Vantaflu\\_aTIV.'}, {'measure': 'Number of Subjects Reporting Unsolicited AEs After Vaccination.', 'timeFrame': 'Day 1 through Day 28 post vaccination', 'description': 'The number of subjects reporting any unsolicited AEs following vaccination with Fluad\\_aTIV and Vantaflu\\_aTIV.'}, {'measure': 'Number of Subjects Reporting Unsolicited Serious Adverse Events (SAEs) After Vaccination.', 'timeFrame': 'Day 1 through Day 28 post vaccination', 'description': 'The number of subjects reporting any unsolicited AEs, SAEs, AEs leading to withdrawal (WD), AEs of special interest (AESI) following vaccination with Fluad\\_aTIV and Vantaflu\\_aTIV.'}]}, 'conditionsModule': {'conditions': ['Influenza']}, 'descriptionModule': {'briefSummary': 'This study will evaluate the safety of an influenza (flu) vaccine in Korean men and women aged 65 years and older.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['OLDER_ADULT'], 'minimumAge': '65 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Males and females aged 65 years and above on the day of enrollment, who were eligible for seasonal influenza vaccination.\n2. In the judgement of the study doctor are determined to be in reasonable health considering their age and able to comply with all study procedures.\n\nExclusion Criteria:\n\n1. History of any serious reaction to flu vaccine, or any materials in the vaccine, and to eggs (including ovalbumin) and chicken protein.\n2. Receipt of another (inactivated) vaccine within 2 weeks, or receipt of a live vaccine within 4 weeks prior to Study Day 1, or planning to receive some other vaccination before the final study visit (about Day 29 after vaccination).\n3. Any condition, which in the opinion of the study doctor, might interfere with the evaluation of the study objective.'}, 'identificationModule': {'nctId': 'NCT01222403', 'briefTitle': 'A Post-marketing Study to Monitor the Safety of a MF59-adjuvanted Influenza Vaccine Administered in Korean Subjects Aged 65 Years or Older', 'organization': {'class': 'INDUSTRY', 'fullName': 'Novartis'}, 'officialTitle': 'A Multicenter, Post-marketing Surveillance Study to Monitor the Safety of Novartis Vaccine MF59-adjuvanted Influenza Subunit Vaccine FLUAD® and Sandoz Korea Vaccine MF59-adjuvanted Influenza Subunit Vaccine VANTAFLU® Administered According to the Prescribing Information in Korean Subjects Aged 65 Years or Older at the Time of Vaccination.', 'orgStudyIdInfo': {'id': 'V70_26'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Fluad', 'description': 'Subjects aged \\>65 years received one dose of investigational MF59-adjuvanted trivalent influenza vaccine (aTIV).', 'interventionNames': ['Biological: Fluad_MF59-adjuvanted trivalent influenza subunit vaccine']}, {'type': 'EXPERIMENTAL', 'label': 'Vantaflu_aTIV', 'description': 'Subjects aged \\>65 years received one dose of investigational MF59-adjuvanted trivalent influenza vaccine (aTIV).', 'interventionNames': ['Biological: Vantaflu_MF59-adjuvanted trivalent influenza subunit vaccine']}], 'interventions': [{'name': 'Fluad_MF59-adjuvanted trivalent influenza subunit vaccine', 'type': 'BIOLOGICAL', 'armGroupLabels': ['Fluad']}, {'name': 'Vantaflu_MF59-adjuvanted trivalent influenza subunit vaccine', 'type': 'BIOLOGICAL', 'armGroupLabels': ['Vantaflu_aTIV']}]}, 'contactsLocationsModule': {'locations': [{'zip': '415-040', 'city': 'Gimpo-si', 'state': 'Gyeonggi-do', 'country': 'South Korea', 'facility': 'KeeTaek Kim internal medicine Clinic', 'geoPoint': {'lat': 37.62361, 'lon': 126.71417}}, {'zip': '580-060', 'city': 'Jeongeup', 'state': 'Jeonrabuk-do', 'country': 'South Korea', 'facility': 'Jiguchon internal medicine Clinic', 'geoPoint': {'lat': 35.60004, 'lon': 126.91699}}, {'zip': '530-390', 'city': 'Mokpo', 'state': 'Jeonranam-do', 'country': 'South Korea', 'facility': '21th Century hana internal medicine clinic', 'geoPoint': {'lat': 34.81282, 'lon': 126.39181}}, {'zip': '540-150', 'city': 'Suncheon', 'state': 'Jeonranam-do', 'country': 'South Korea', 'facility': 'JoongAng family medicine Clinic', 'geoPoint': {'lat': 34.9505, 'lon': 127.48784}}, {'zip': '120-752', 'city': 'Sinchon-dong', 'state': 'Seoul', 'country': 'South Korea', 'facility': 'Yonsei Universtity College of Medicine'}, {'zip': '300-110', 'city': 'Daejeon', 'country': 'South Korea', 'facility': 'Hangajok internal medicine clinic', 'geoPoint': {'lat': 36.34913, 'lon': 127.38493}}, {'zip': '305-313', 'city': 'Daejeon', 'country': 'South Korea', 'facility': 'Ju Saengmyeong internal medicine Clinic', 'geoPoint': {'lat': 36.34913, 'lon': 127.38493}}, {'zip': '306-010', 'city': 'Daejeon', 'country': 'South Korea', 'facility': 'Daejeon hospital', 'geoPoint': {'lat': 36.34913, 'lon': 127.38493}}, {'zip': '770-160', 'city': 'Daejeon', 'country': 'South Korea', 'facility': 'SaeSeoul internal medicine and radiology Clinic', 'geoPoint': {'lat': 36.34913, 'lon': 127.38493}}, {'zip': '404-190', 'city': 'Incheon', 'country': 'South Korea', 'facility': 'SeoIncheon catholic clinic', 'geoPoint': {'lat': 37.45646, 'lon': 126.70515}}, {'zip': '405-224', 'city': 'Incheon', 'country': 'South Korea', 'facility': 'TaeIl Jang internal medicine Clinic', 'geoPoint': {'lat': 37.45646, 'lon': 126.70515}}, {'zip': '407-806', 'city': 'Incheon', 'country': 'South Korea', 'facility': 'SeokYeon Kim internal medicine clinic', 'geoPoint': {'lat': 37.45646, 'lon': 126.70515}}, {'zip': '110-744', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Seoul National University Hospital', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '120-752', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Yonsei University Severance Hospital', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '131-865', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Seoul medical center', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '135-271', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Global care internal medicine clinic', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '138-201', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Yeonsei Koum internal medicine Clinic', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '140-887', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Soon Chun Hyang University Hospital', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '143-203', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Gikim internal medicine clinic', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '143-210', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Lee internal medicine clinic', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '150-950', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Kangnam Sacred Heart Hospital', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'city': 'Seoul', 'country': 'South Korea', 'facility': 'Korea University Guro Hospital', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'city': 'Seoul', 'country': 'South Korea', 'facility': 'Yonsei University Severance Hospital', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Novartis Vaccines', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}